Supplementary materials for: The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials

Description

Table I. Trial Registration Table II: Efficacy Outcomes Scales Table III: Proportion of Patients Achieving EASI 75 During Treatment in the Escape Arm Table IV. Overview of Adverse Events Table V. Rescue Therapy Usage from Week 16 to Week 52 Figure 1. Study Design for ADvocate1 and ADvocate2 Figure 2. ADvocate1 and ADvocate2 Pooled Patient Disposition Figure 3. Time Course of Response (Supportive Analysis)

Categories

Funding

Licence